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OBJECTIVES: Inflammatory molecules play a role in the development of atherosclerosis, which is the primary
origin of cardiovascular disorders. However, to the best of our knowledge, no study has attempted to investi-
gate the relationship between these circulating molecules and the prediction of cardiovascular risk. The present
study aimed to investigate the relationships of vascular cell adhesion molecule-1, intercellular adhesion
molecule-1, E-selectin and matrix metalloproteinase 9 serum concentrations with the extent of coronary lesions.
METHODS: Seventy-four individuals who were undergoing coronary angiography for the first time for diagnostic
purposes were enrolled in this study. The extent of the coronary lesion was assessed using the Friesinger Index, and
subjects were classified into four groups: no lesions, minor lesions, intermediate lesions and major lesions. Serum
biochemical parameters and serum concentrations of vascular cell adhesion molecule-1, intercellular adhesion
molecule-1, E-selectin and matrix metalloproteinase 9 were analyzed.
RESULTS: The vascular cell adhesion molecule-1 concentration was higher than 876 ng/mL in individuals with
intermediate and major lesions (po0.001 and p=0.020, respectively). Moreover, logistic regression analysis
showed that these patients had an increased risk of having an intermediate lesion (p=0.007). Interestingly, all
individuals with major lesions had vascular cell adhesion molecule-1 concentrations higher than 876 ng/mL.
No association was found between the concentrations of the other proteins and the Friesinger Index.
CONCLUSIONS: Serum vascular cell adhesion molecule-1 may be associated with the extent of coronary lesions.
Moreover, it may represent an alternative to improve the cardiovascular risk classification in patients without
acute coronary syndrome.
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’ INTRODUCTION
Cardiovascular disease is the leading cause of death world-
wide. Obtaining knowledge about its physiopathology seems
to be the best approach to reducing morbidity, mortality, and
health care costs, since there are no non-invasive methods,
laboratory tests or clinical symptoms that are capable of
detecting which individuals will develop coronary artery
disease (CAD) (1).
Atherosclerosis, the primary origin of most common car-
diovascular disorders, is an inflammatory process with slow
and progressive development. This process involves increa-
sed expression of cellular adhesion molecules and enhanced
cell migration, low-density lipoprotein (LDL) recruitment
and fibrous tissue proliferation that lead to partial or total
blood flow obstruction (2-4). During this process, migrating
cells secrete more inflammatory cytokines and matrix metal-
loproteinases, leading to plaque rupture (5) and thrombus
formation (4). The detection of atherosclerotic plaques at this
inflammatory stage could allow the prevention of future
acute cardiovascular events (6).
Studies have shown that the determination of soluble
adhesion molecules, such as intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) andDOI: 10.6061/clinics/2018/e203
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E-selectin, can reflect the inflammatory process in the endothe-
lium. Together, these molecules form an integrated and over-
lapping system for the transport of leukocytes into the
vascular wall and play an active role in the development of
atherosclerotic plaques (7). Moreover, matrix metalloprotei-
nases (MMPs) play important roles in thrombogenesis by
disrupting atherosclerotic plaques and participating in the
degradation of the extracellular matrix (8,9).
However, few studies have shown an association between
increased expression of these proteins in tissues and their
soluble level in the plasma. Also, to the best of our know-
ledge, no studies have associated these molecules with the
early atherosclerotic process and the coronary atherosclerotic
burden in humans (2,10,11). Previous studies have investi-
gated these molecules in patients with acute coronary syn-
drome and even post-infarction patients, but no study has
evaluated these molecules prior to cardiovascular events.
Therefore, the aim of this study was to investigate a
possible relationship between circulating VCAM-1, ICAM-1,
E-selectin or MMP9 and the extent of coronary lesions in
patients without acute coronary syndrome nor post-infarction
patients. These results may contribute to the identification
of potential biomarkers and the development of non-invasive
methods for the diagnosis of atherosclerosis, thus reducing
health costs and cardiovascular risk.
’ MATERIALS AND METHODS
Study population
Seventy-four male and female individuals aged between
30 to 74 years who were undergoing coronary angiography
at the hemodynamics Department of University Hospital
Onofre Lopes (HUOL) for diagnostic purposes were enrolled
in the present study. Subjects with cardiomyopathy, includ-
ing Chagas disease, heart valve disease, congenital diseases,
and pericarditis, and subjects with an angioplasty or stent
were excluded from this study. Additionally, patients with
familial hypercholesterolemia or the presence of chronic kid-
ney disease, liver failure, endocrine disorders (except for
diabetes mellitus), inflammatory diseases, malignant dis-
eases, blood disorders, autoimmune diseases were excluded.
The study was conducted in accordance with the guidelines
set by the Ethics in Research Committee of the Federal
University of Rio Grande do Norte and complies with the
Declaration of Helsinki (protocol CAAE 0001.0.051.294-11).
All participants signed an informed consent form.
Extent of coronary lesions
The extent of the coronary lesions was assessed using the
Friesinger Index (12–14). Each of the three main coronary
arteries (anterior descending, circumflex and right coronary)
was scored separately from zero to five. The subjects were
classified as follows: no lesion when the Friesinger Index was
equal to 0; minor lesion when the Index varied from 1–5;
intermediate lesion when the Index varied from 6–10; and
major lesion when the Index varied from 11–15, as adapted
from Chagas et al. (15).
Blood samples and biochemical analysis
Peripheral venous blood samples were obtained from the
patients. Fasting serum glucose, total cholesterol and fra-
ctions, urea, creatinine K, uric acid, alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) were measured
using colorimetric and colorimetric-enzymatic (Labtest, Minas
Gerais, Brazil) methods on a semi-automatic biochemical
analyzer (BIO-2000 IL, Bioplus, SP, Brazil). The LDL level was
calculated according to the formula described by Friedewald
et al. (16).
A multiplex immunoassay using polystyrene beads based
on the Luminex technology was performed since the VCAM-
1, ICAM-1, E-selectin and MMP9 molecules were found in
small amounts in the blood. The Millipexs MAP Human
CVD Panel 1 Immunoassay Kit (Merck KGaA, Darmstadt,
Germany) was used according to the manufacturer’s instruc-
tions. Briefly, the samples were mixed with antibody-linked
polystyrene beads in 96-well filter-bottom plates and incu-
bated at room temperature for 2h, followed by overnight
incubation at 4oC. The plates were vacuum filtered, washed
twice with wash buffer, and then incubated with a bio-
tinylated detection antibody for 1h at room temperature.
Streptavidin–phycoerythrin was added to the sample. After
incubation for 30 min at room temperature and two addi-
tional vacuum washes, the samples were resuspended in
reading buffer. Each sample was measured in duplicate.
The plates were read using a Luminexs 100/200t System
(Luminex, Austin, TX, USA) with a lower bound of 100 beads
per sample per cytokine.
Statistical analysis
The statistical analyses were performed using the SPSS
software v20.0 (SPSS Inc., Chicago, IL, USA). The data were
categorized in two conditions: 1. Friesinger Index groups (no
lesion, minor lesion, intermediate lesion and major lesion)
and 2. Tertile concentrations of inflammatory molecules
(1st, 2nd and 3rd). Categorical variables were shown as per-
centages and compared using the Chi-square test. Contin-
uous variables were presented as the mean and standard
deviation and compared using the Kruskal–Wallis test or
ANOVA, followed by Tukey’s post hoc test according to the
normality of the distribution assessed using the Kolmogorov-
Smirnov test. Spearman’s correlation was used to calculate
correlations between the inflammatory protein concentrations
and the Friesinger Index. Logistic regression analyses were
used to evaluate the relationships between the increases in
serum inflammatory molecules and the Friesinger Index. The
level of statistical significance was set as po0.05.
’ RESULTS
The patients were classified into four groups according to
the extent of the coronary lesions evaluated by the Friesinger
Index as follows: no lesion (31.0%), minor lesion (29.8%),
intermediate lesion (27.0%) and major lesion (12.2%). The
demographic, anthropometric, clinical and biochemical data
collected from these groups are shown in Table 1 and Table 2.
Significant differences in the clinical and biochemical data
were not found among the groups.
The categorization of the adhesion molecules and MMP9
into tertiles showed that patients with intermediate and
major lesions had VCAM-1 concentrations 4876 ng/mL
(2nd and 3rd tertiles), whereas patients with no or minor
lesions had VCAM-1 concentrationso876 ng/mL (1st tertile,
po0.05, Figure 1).
Additionally, the patients with VCAM-1 concentrations
4876 ng/mL had a 9.81-fold higher risk of having inter-
mediate lesions (po0.01; OR: 9.81; 95% CI: 1.84 – 52.38, Table 3).
In this study, all patients with major lesions had VCAM-1
concentrations 4876 ng/mL. E-selectin, ICAM-1 and MMP9
2
VCAM-1 and the extent of coronary lesions
Santos JC et al.
CLINICS 2018;73:e203
were not associated with the Friesinger Index, although
VCAM-1 was correlated with ICAM-1 and the extent of
the coronary lesion (po0.01, r2=0.40; and p=0.02, r2=0.29,
respectively).
’ DISCUSSSION
The primary origin of CAD is atherosclerosis, which is a
chronic inflammatory process that induces the expression of
adhesion molecules at the endothelial membrane. VCAM-1,
ICAM-1 and E-selectin promote the connection of leukocytes
and their migration into the intima, whereas MMP9, a metal-
loproteinase, plays a special role in the instability of athe-
rosclerotic plaques. These molecules can also be found in the
serum in a soluble form due to the proteolytic rupture of
cellular membranes in which adhesion molecules are expres-
sed. Therefore, their measurement can be evaluated in seve-
ral clinical situations in which inflammation is a causal
contributor, making these molecules easily accessible serum
markers (2,17,18).
Interestingly, in the present study, it was observed that
patients with intermediate and major lesions had high
VCAM-1 concentrations (4876 ng/mL). In addition, the
logistic regression analysis indicated that patients subjected
to coronary angiography with VCAM-1 levels higher than
876 ng/mL had a 9.8-fold greater risk of having athero-
sclerotic lesions (intermediate lesions), whereas ICAM-1
showed no correlation with the Friesinger Index. All patients
with major lesions had a VCAM-1 concentration4876 ng/mL,
thereby suggesting a possible VCAM-1 cut-off value that may
aid in the determination of the extent of coronary lesions.
A previous study with 855 patients diagnosed with stable
carotid atherosclerosis over a 6.2-year period observed that
VCAM-1 values higher than 837 ng/mL increased the
cardiovascular mortality risk by 2.5-fold and predicted future
fatal cardiovascular events, whereas ICAM-1 values higher
than 335 ng/mL increased that risk by 3.4-fold; these results
indicated that these molecules were strong and independent
predictors of mortality in patients with stable carotid athero-
sclerosis (2). In contrast, another study that enrolled 15 patients
with a high cardiovascular risk during stent implantation found
that the VCAM-1 serum concentrations were not different from
the basal levels (prior to stent implantation) and were
independent of the ICAM-1 serum concentration (19). Despite
these controversial results, to the best our knowledge, no study
has attempted to evaluate the association of serum VCAM-1
with cardiovascular risk in patients without acute coronary
syndrome, thus supporting the needed for new studies.
Table 1 - Demographic, anthropometric and clinical data from patients classified according to the extent of the coronary lesion.
Variable Total (74) No lesion (23) Minor lesion (22) Intermediate lesion (20) Major lesion (9) p-value
Age, years 60±10 56±9 61±10 63±10 62±7 0.061
Gender, male 55.4 (41) 43.5 (10) 59.1 (13) 70.0 (14) 44.4 (4) 0.307
BMI, kg/m2 26.5±5.4 27.4±4.3 25.5±7.6 26.4±4.2 26.3±3.4 0.752
Obesity, % 17.6 (13) 26.1 (6) 18.2 (4) 15.0 (3) 0.0 (0) 0.437
Dyslipidemia, % 85.1 (63) 69.6 (16) 90.9 (20) 95.0 (19) 100 (9) 0.085
Diabetes, % 32.4 (24) 34.8 (8) 22.7 (5) 35.0 (7) 44.4 (4) 0.647
Hypertension, % 81.1 (60) 78.3 (18) 81.8 (18) 80.0 (16) 88.9 (8) 0.919
Diastolic pressure, mmHg 84±18 80±9 83±22 87±17 89±29 0.588
Systolic pressure, mmHg 143±26 137±23 143±24 151±34 141±20 0.472
Treated hypertension, % 77.0 (57) 78.3 (18) 81.8 (18) 70.0 (14) 77.8 (7) 0.715
Sedentary lifestyle, % 55.4 (41) 52.2 (12) 50.0 (11) 60.0 (12) 66.7 (6) 0.804
Alcoholism, % 16.2 (12) 21.7 (5) 18.2 (4) 5.0 (1) 22.2 (2) 0.445
Smoking, % 23.0 (17) 21.7 (5) 18.2 (4) 25.0 (5) 33.3 (3) 0.826
AIM family history, % 43.2 (32) 39.1 (9) 31.8 (7) 50.0 (10) 66.7 (6) 0.294
Data are shown as the mean± SD or the percentage for categorical variables (number of patients) and compared using the Kruskal–Wallis test or ANOVA
for continuous variables and the Chi-square test for categorical variables. BMI: body mass index; and AMI: acute myocardial infarction. p-values o0.05
were considered statistically significant.
Table 2 - Biochemical data according to the extent of the coronary lesion.
Variable Total (74) No lesion (23) Minor lesion (22) Intermediate lesion (20) Major lesion (9) p-value
Glucose, mmol/L 6.17±2.95 5.76±2.34 5.68±1.82 7.10±4.37 6.38±2.62 0.408
Total cholesterol, mmol/L 4.73±1.20 4.47±1.04 4.58±1.02 5+11±1.44 4.91±1.42 0.305
HDL cholesterol, mmol/L 0.98±0.27 1.04±0.31 0.93±0.22 0.93±0.26 1.03±0.29 0.414
LDL cholesterol, mmol/L 2.86±1.07 2.64±0.90 2.68±0.89 3.16±1.31 3.22±1.28 0.261
Triglycerides, mmol/L 1.97±1.48 1.70±1.30 2.11±1.44 2.37±1.87 1.46±0.76 0.157
ALT, mKat/L 0.51±0.36 0.50±0.39 0.52±0.23 0.48±0.45 0.58±0.39 0.298
AST, mKat/L 0.57±0.32 0.65±0.38 0.54±0.29 0.51±0.22 0.63±0.39 0.639
Urea, mmol/L 13.45±3.72 13.03±3.68 13.52±3.26 14.10±4.40 12.98±3.82 0.864
Creatinine K, mmol/L 84.0±258 85.0±24.2 81.6±20.0 89.7±28.3 74.6±36.7 0.505
Uric acid, mmol/L 0.29±0.09 0.29±0.10 0.30±0.10 0.28±0.10 0.28±0.08 0.965
E-selectin, ng/mL 32.5±16.8 33.5±19.8 30.4±14.6 34.4±17.3 30.6±14.6 0.855
VCAM-1, ng/mL 990.0±270.3 994.3±330.3 899.7±214.7 1080.2±282.0 998.9±118.3 0.196
ICAM-1, ng/mL 152.2±53.7 152.6±68.4 161.9±58.0 144.9±39.5 144.0±21.1 0.695
MMP9, ng/mL 324.2±156.4 348.8±198.5 302.9±127.7 351.8±146.3 252.2±102.6 0.325
Number of individuals in parentheses. Continuous variables are presented as the mean± standard deviation and compared using the Kruskal–Wallis test
or ANOVA. Categorical variables were compared using the Chi-square test. HDL: high-density lipoprotein; LDL: low-density lipoprotein; AST: alanine
aminotransferase; and ALT: aspartate aminotransferase. p-values o0.05 were considered statistically significant.
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No significant difference was observed between serum
levels of ICAM-1 and the extent of coronary lesions; however,
an indirect positive correlation between these factors was
revealed, as VCAM-1 correlated with the Friesinger Index and
VCAM-1 correlated with ICAM-1 serum levels. This result
could be due to the lower ICAM-1 concentrations found in
the subjects enrolled in the present study (o250 ng/mL).
Moreover, the considerable controversies were found in the
literature about the predictive values of ICAM-1 and VCAM-1
may be explained by the characteristics of both molecules.
ICAM-1 seems to be a natural marker of pro-inflammatory
conditions, whereas VCAM-1 is rapidly induced by pro-
atherosclerotic circumstances.
Regarding MMP9 and E-selectin, significant results were
not found in the present study. MMP9 plays a critical role
in the later stages of atherosclerotic lesions, particularly in
the rupture of the atherosclerotic plaque (17,20). MMP9
concentrations were significantly increased in aortic samples
from 89 patients who underwent a surgical procedure for
abdominal aortic aneurysms (21). Also, soluble MMP9 was
associated with vulnerable atherosclerotic plaques in 88 patients
who experienced a major adverse cardiovascular event in a
cohort study over a 3-year period (20). In the present study,
only patients with no history of acute coronary syndrome
who underwent coronary angiography for the first time
were included, and we found that 60.8% of our patients had
only minor or no atherosclerotic lesions. These aspects may
account for the absence of high serum levels of MMP9 in
our study population.
Regarding E-selectin, the absence of an association between
E-selectin and the extent of coronary lesions in the present
study could be explained by the involvement of this molecule
in the early nonspecific stages of leukocyte adherence and
rolling. This result was also observed by other authors, whom
also did not associate soluble E-selectin with adverse clinical
outcomes in 855 patients diagnosed with stable carotid athe-
rosclerosis (2) or in a study evaluating 65 patients with acute
coronary syndrome (22).
The present results are important, particularly regarding
VCAM-1 serum levels, because no atherosclerotic lesions
Figure 1 - Friesinger Index in patients undergoing coronary angiography for the first time stratified by tertiles of serum protein levels.
(A) Individuals with higher VCAM-1 concentrations (X876 ng/mL) are likely to have higher Friesinger Index values. Serum (B) ICAM-1,
(C) MMP9 and (D) E-selectin levels were not associated with increased Friesinger Index values. Data are shown as the mean ± SD. *
represents a significant difference compared with the 1st tertile.
Table 3 - Logistic regression analysis: influence of increased VCAM-1 concentrations (4876 ng/mL) on the extent of the coronary lesion.
Dependent variable Covariable OR (95% CI) p-value
VCAM-1 4876 ng/mL No lesion 1
Minor lesion 1.309 0.405-4.226 0.652
Intermediate lesion 9.818 1.840-52.384 0.007
Logistic regression analysis was performed to determine the Friesinger Index using a VCAM-1 serum concentration4876 ng/mL as a dependent variable.
This analysis was not performed with the Major lesion group because, in this study, all patients with major lesions had VCAM-1 concentrations 4876 ng/mL.
OR: odds ratio; and CI: confidence interval.
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were detected in 31% of the patients, and the high
frequency of patients without lesions who were subjected
to an invasive procedure in both studies indicates a clear
need to establish new tests to complement and aid CAD
diagnosis. Similar data were recently reported in a study of
100 patients of both genders undergoing coronary angio-
graphy for diagnostic purposes, showing that 37% of those
patients had no atherosclerotic lesions (12). Our hypothesis
is also supported by other authors, whom have emphasized
the absence of non-invasive methods, clinical symptoms or
laboratory tests that are capable of detecting individuals
who will develop CAD (1).
A major limitation of the present study was the small
sample size, as our pilot study population consisted of
patients without previous acute cardiac events who were
referred for diagnostic coronary angiography for the first
time. However, it is important to highlight that this was the
first study to evaluate circulating inflammatory molecules
and their relationships with the extent of coronary lesions in
patients without acute coronary syndrome.
Some of the established major vascular risk factors are not
observed in over 20% of patients who develop coronary
events (23). Thus, using markers involved in the athero-
sclerotic process may lead to better, earlier and more accurate
risk predictions for CVDs. In addition, non-invasive methods
and laboratory tests play an important role in decreasing
health costs and improving quality of life among patients.
In conclusion, circulating VCAM-1 might be associated
with the extent of coronary lesions in patients with a risk of
developing acute coronary syndrome. In addition, this result
suggests that VCAM-1 may also be associated with the pre-
diction of cardiovascular disease and the severity of athero-
sclerosis. Further investigation is required to validate this
hypothesis and to determine whether monitoring VCAM-1
serum levels may be valuable for the assessment of cardio-
vascular risk.
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